What is the recommended pathological evaluation, diagnostic workup, and comprehensive management for an adult male presenting with a scrotal mass suspected to be lymphoma?

Scrotal Lymphoma: Pathology, Diagnosis, and Comprehensive Management

Pathological Evaluation

Primary testicular lymphoma (PTL) is predominantly diffuse large B-cell lymphoma (DLBCL), accounting for the vast majority of cases, and requires excisional tissue biopsy via radical inguinal orchiectomy for definitive diagnosis 1, 2. Fine-needle aspiration is inadequate for initial diagnosis 3.

Key Pathological Features:

• Histology: Most commonly intermediate-grade B-cell lymphoma (78.3% present as Stage IE at diagnosis) 4
• Immunohistochemistry: Essential for confirming B-cell lineage and CD20 positivity 5, 6
• MYC and BCL2 rearrangements: Indicate poor prognosis and should be assessed 6
• WHO classification: Pathology report must use current WHO classification system 7

Critical Pitfall: An elevated AFP level indicates nonseminoma (germ cell tumor), not lymphoma—these patients must be managed as testicular cancer, not lymphoma 8.

Diagnostic Workup

Initial Evaluation (Pre-Orchiectomy):

Scrotal ultrasound with Doppler is mandatory for any scrotal mass 9. Any hypoechoic mass with vascular flow is highly suggestive of malignancy 9.

Serum tumor markers must be drawn before orchiectomy 9:

• AFP (alpha-fetoprotein)
• β-hCG (human chorionic gonadotropin)
• LDH (lactate dehydrogenase)

Staging After Histological Confirmation:

PET-CT is the gold standard for staging and must include 3, 10, 6:

• Whole-body imaging to detect nodal and extranodal involvement
• Bone marrow assessment (PET-CT is adequate; biopsy only if PET-negative but clinical suspicion remains) 3

Additional mandatory studies 11, 5:

• Complete blood count and comprehensive metabolic panel including LDH and uric acid
• HIV, Hepatitis B and C screening
• CNS evaluation in high-risk patients: MRI brain and CSF analysis (cytology and flow cytometry) for patients with elevated LDH, >1 extranodal site, or testicular involvement 5, 3
• Cardiac assessment if anthracyclines planned: echocardiography or MUGA scan 7

Risk stratification using International Prognostic Index (IPI) is mandatory 11, 5, 6.

Critical Pitfall: Testicular lymphoma has extremely high CNS relapse risk—CNS prophylaxis is mandatory, not optional 5.

Comprehensive Management

Surgical Management:

Radical inguinal orchiectomy is the primary treatment 1, 2. Scrotal violation must be avoided.

Contralateral testicular prophylactic irradiation should be considered in localized disease due to high bilateral involvement risk 5.

Systemic Therapy:

For CD20-positive DLBCL (standard presentation), R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone) every 21 days for 6-8 cycles is the standard of care 11, 5. Alternatively, Pola-R-CHP may be considered based on IPI scores 6.

Dose reductions should be avoided—use hematopoietic growth factors prophylactically for febrile neutropenia in patients treated with curative intent 11.

CNS Prophylaxis (Mandatory):

Intrathecal methotrexate or cytarabine must be administered 5. The evidence suggests intrathecal injections alone may not be optimal, and high-dose systemic methotrexate should be considered 5.

Consolidation Therapy:

Rituximab maintenance substantially prolongs progression-free survival in relapsed disease 12, though its role in first-line therapy for testicular lymphoma specifically remains investigational.

Radiotherapy to bulky disease sites has NOT proven beneficial in DLBCL 11, 5 and should generally be avoided except in specific circumstances.

Response Assessment:

PET-CT after 3-4 cycles (interim) and after completion of therapy 5, 6:

• Interim PET predicts clinical outcome and can guide treatment intensification
• Post-treatment PET is highly recommended for defining complete remission
• If PET-positive post-treatment with therapeutic consequences, histological confirmation is strongly recommended 5

Bone marrow biopsy repeated only if initially involved 5.

Follow-Up Protocol

Structured surveillance is critical given high relapse rates (30-40% of DLBCL patients relapse) 6:

Years 1-2:

• History and physical examination every 3 months 7, 5
• Blood count and LDH at 3,6,12, and 24 months 11, 5
• CT imaging at 6,12, and 24 months 11
• Routine surveillance PET is NOT recommended 5

Years 3-5:

• Clinical evaluation every 6 months 7, 5

Beyond 5 years:

• Annual follow-up with attention to secondary malignancies and late toxicities 7, 5

Monitor specifically for:

• CNS relapse (most common extranodal relapse site)
• Contralateral testicular involvement
• Secondary leukemia 12
• Cardiotoxicity from anthracyclines 6
• Thyroid dysfunction if neck irradiation given 7

Relapsed/Refractory Disease

For relapse <12 months or refractory disease in fit patients (<65 years): Salvage chemotherapy (R-DHAP, R-ESHAP, R-ICE) followed by high-dose therapy with autologous stem cell transplantation is recommended 7.

For relapse ≥12 months: Repeat biopsy is mandatory to confirm CD20 positivity and exclude transformation 7.

CAR-T cell therapy is the gold standard in second-line for CART-naïve patients refractory or relapsing within <1 year 6.

Critical Pitfall: Primary testicular lymphoma is highly aggressive with dismal prognosis if systemic metastases present at diagnosis 2. Multidisciplinary team involvement (urology, medical oncology, radiation oncology) is essential 1.